TSRA-196

About Tessera Therapeutics

Tessera Therapeutics is a Flagship Pioneering-incubated biotech developing a proprietary 'Gene Writing' platform, which it positions as a new category of genetic medicine beyond traditional gene editing and therapy. The technology is designed to make both small and large, permanent genomic alterations and is coupled with a non-viral delivery system. The company has advanced its lead in vivo program, TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD), into clinical development, with FDA Fast Track and Orphan Drug designations, and is also pursuing an HIV cure with grant support. As a private, pre-revenue company, Tessera is focused on translating its platform into potentially curative therapies for major unmet medical needs.

Therapeutic Areas

Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs